Johnson and Johnson: Nipocalimab Demonstrates Significant Clinical Improvement in Disease Activity and IgG Reduction in Phase 2 Sjogren's Disease Study
November 15, 2024
November 15, 2024
NEW BRUNSWICK, New Jersey, Nov. 15 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Adults with moderately-to-severely active Sjogren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels
Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moder . . .
* * *
Adults with moderately-to-severely active Sjogren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant reductions in IgG and autoantibody levels
Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moder . . .